SANOFI-AVENTIS REAFFIRMS COMMITMENT TO ALLIANCE WITH REGENERON PHARMACEUTICALS Partners Approve Broad-based Cancer Development Program for the VEGF Trap Regeneron To Receive $25 million Clinical Development Milestone Payment Plus Additional $25 Million Payment
Tuesday, January 11, 2005 1 min read
Key Takeaway: SANOFI-AVENTIS REAFFIRMS COMMITMENT TO ALLIANCE WITH REGENERON PHARMACEUTICALS Partners Approve Broad-based Cancer Development Program for the VEGF Trap Regeneron To Receive $25 million Clinical Development Milestone Payment Plus Additional $25 Million Payment
Full Press Release Details
SANOFI-AVENTIS REAFFIRMS COMMITMENT TO ALLIANCE WITH REGENERON PHARMACEUTICALS Partners Approve Broad-based Cancer Development Program for the VEGF Trap Regeneron To Receive $25 million Clinical Development Milestone Payment Plus Additional $25 Million Payment.